Fintel reports that on October 8, 2025, HC Wainwright & Co. reiterated coverage of Ionis Pharmaceuticals (NasdaqGS:IONS) with ...

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look at where Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) stands against the other ...

Ionis has faced a declining revenue trajectory over the medium term, with a 1.4% average annual drop over three years versus 5.3% growth for the S&P 500. The last twelve months reflect a steeper 7.6% ...

Ionis Pharmaceuticals (IONS) has been beaten down lately with too much selling pressure. While the stock has lost 13.5% over the past four weeks, there is light at the end of the tunnel as it is now ...